Evaluating Oral Impact® with Anti PD-1 Treatment for Advanced Melanoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of Oral Impact® in reducing immune-related adverse events in patients with inoperable locally advanced or metastatic melanoma. A total of 20 patients will receive Oral Impact® for a specified duration before starting treatment with nivolumab, an anti-PD-1 therapy. The study will compare outcomes with historical data from similar patients who did not receive Oral Impact®. The goal is to assess whether this intervention can improve patient tolerance to the standard treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥ 18 years;
2. Histologically confirmed stage III (unresectable) or stage IV Cutaneous Melanoma;
3. PD-L1 evaluation and as per standard clinical practice, patients with PD-L1 \< 1% will be treated with anti PD1 based regimen and patients with PD-L1\>1% will be treated with anti-PD1 in monotherapy;
4. Anti-PD1 (Nivolumab) or anti PD1 based regimen (Nivolumab plus Ipilimumab or Nivolumab plus Relatlimab) planned as per standard clinical practice and decision by the treating oncologist; ;
5. Measurable disease by computed tomography (CT) or Magnetic Resonance Imaging (MRI) per RECIST 1.1 criteria;
6. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1;
7. Screening laboratory values must meet the following criteria before starting the treatment:

   1. WBCs ≥2000/μL
   2. Neutrophils ≥1500/μL
   3. Platelets ≥100 x 10³/μL
   4. Hemoglobin ≥9.0 g/dL
   5. Serum creatinine of ≤1.5 times the upper normal limits or creatinine clearance \>40 mL/minute
   6. AST ≤ 3 times the upper normal limits
   7. ALT ≤ 3 times the upper normal limits
   8. Total bilirubin ≤1.5 times the upper normal limits (except patients with Gilbert Syndrome who must have total bilirubin \<3.0 mg/dL)
8. Prior palliative radiotherapy must have been completed at least 2 weeks prior to study drug administration;
9. Patients of reproductive potential, must use adequate contraception methods;
10. Signed written consent form;

Exclusion Criteria:

1. Active brain metastases;
2. Patients with previous malignancies unless a complete remission was achieved at least 2 years prior to study entry;
3. Patients with prior systemic anticancer therapy for unresectable or metastatic melanoma;
4. Any serious or uncontrolled medical disorder or active infection that, in the opinion of the investigator, may increase the risk associated with study participation, study drug administration, or would impair the ability of the patient to receive protocol therapy;
5. Presence of active, known, or suspected autoimmune disease;
6. Subjects with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of treatment;
7. Participation in any interventional drug or medical device study within 30 days prior to treatment start;
8. Patients with active hepatitis B (defined as having a positive hepatitis B surface antigen \[HBsAg\] test at screening) or active C hepatitis or active HIV;
9. History of severe hypersensitivity reactions to other monoclonal antibodies;
10. Pregnant and breast-feeding women;
11. Patients of reproductive who refuse to use effective methods of contraception.

Where it's running

• Istituto Nazionale Tumori IRCCS - Fondazione "G. Pascale"
  Naples, Italy Recruiting

Study contacts

• Study coordinator: Paolo A. Ascierto
• Email: p.ascierto@istitutotumori.na.it; melaimpact@cr-technology.com
• Phone: +39 08117775088

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combo of tunlametinib, pucotenlimab, and hydroxychloroquine in NRAS-mutant melanoma

  This study tests whether adding hydroxychloroquine to tunlametinib and pucotenlimab helps people with NRAS-mutant melanoma.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07750067

• Fiber to boost gut bacteria and immunotherapy response in advanced melanoma

  In people with advanced melanoma starting immunotherapy, this trial tests whether increasing dietary fiber can grow beneficial gut bacteria and improve treatment response.

  Recruiting Phase 2 Radboud University Medical Center · Nijmegen, Gelderland and 1 other locations · NCT07686835

• Comparing two immunotherapy combinations and their immune effects in unresectable or metastatic melanoma

  This will test whether two different first-line immunotherapy combinations produce different immune responses in tumors and blood of people with unresectable or metastatic melanoma.

  Recruiting University of Pittsburgh · Pittsburgh, Pennsylvania · NCT07223411

• Anti‑PD‑1 with a postbiotic for advanced, treatment‑naïve cutaneous melanoma

  This trial will test whether adding a postbiotic to anti‑PD‑1 immunotherapy helps boost tumor immune markers and improve outcomes in people with untreated stage IIIC or IV cutaneous melanoma.

  Recruiting Azienda Ospedaliera di Perugia · Bari, BA and 4 other locations · NCT07050940

• Using modified T cells to treat advanced melanoma and sarcoma

  This study is testing a new treatment that uses modified T-cells to see if it can help people with advanced melanoma and sarcoma fight their cancer better.

  Recruiting Phase 1 Centre Hospitalier Universitaire Vaudois · Lausanne, Canton of Vaud and 1 other locations · NCT06889766

• Combining multimodal tumor ablation with immunotherapy for liver metastases

  This trial will test whether adding the immunotherapy drug pucotenlimab to multimodal thermal ablation helps people with liver metastases from colorectal cancer, triple-negative breast cancer, or melanoma.

  Recruiting Phase 2 Fudan University · Shanghai · NCT06889610

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.